Hims & Hers vs Thirty Madison

Side-by-side comparison of model-estimated upside.

Hims & Hers

+8%

est. 2Y upside i

Healthcare

Rank

#2474

Sector

Telehealth

Est. Liquidity

~2Y

Data Quality

Data: High

Hims & Hers presents a moderate upside opportunity for a job seeker, driven by its strong historical revenue growth (59% in 2025) and recent profitability ($128M net income).

Last updated: March 10, 2026

Thirty Madison

-55%

est. 2Y upside i

Healthcare

Rank

#2650

Sector

HealthTech

Est. Liquidity

~2Y

Data Quality

Data: Medium

The combined Remedy Meds and Thirty Madison entity operates in a fast-growing digital health market, with Remedy Meds generating over $450M in revenue and Thirty Madison over $220M, both profitable.

Last updated: March 10, 2026

Note: These companies have different risk levels. Hims & Hers (Moderate Risk) and Thirty Madison (Higher Risk). A higher expected upside in a higher-risk company comes with greater uncertainty. Compare within the same risk tier for more meaningful evaluation.

Upside Comparison

Expected Upside

Hims & Hers

+8%

Thirty Madison

-55%

Disclaimer: These rankings are AI-generated estimates and do not constitute financial or career advice. Always conduct your own due diligence.